News

Research highlights the benefits of natalizumab during pregnancy for women with multiple sclerosis, showing reduced disease activity and improved outcomes.

The ongoing PERSEUS trial explores tolebrutinib's potential as a treatment for primary progressive multiple sclerosis, with results anticipated soon.

Host Jeffrey Wilken, PhD, chats with Marie Namey, APRN, MSCN, about the first day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

Jeff Smith, PhD, chief executive officer at Precision Biosciences, explained the clinical potential and gene-editing mechanism of PBGENE-DMD, a one-time therapy targeting dystrophin mutations in Duchenne muscular dystrophy.

New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple sclerosis.

The pair of neurologists highlight key advances needed in imaging, trial design, and preclinical modeling to drive remyelination breakthroughs in MS.

The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

The 39th CMSC Annual Meeting is set to be held May 28-31, 2025, in Phoenix, Arizona. The International Journal of MS Care has published the abstracts.

Nuvig's NVG-2089 shows promise in CIDP treatment, offering a safer, more efficient alternative to IVIg with a patient-friendly trial design.

In this episode, a duo of neurologists examine the plausibility, limitations, and risks of holistic approaches to remyelination—and what patients should prioritize or avoid.

Panelists Ari Green, MD, and Paul Tesar, PhD, explore the scientific rationale and clinical complexity behind promising remyelination agents currently in development for multiple sclerosis.

BioVie initiates a phase 2 trial for bezisterim, targeting neurological symptoms of Long COVID, aiming to improve patient quality of life.

Here's some of what is coming soon to NeurologyLive® this week.

Episode 4 covers how aging and disease duration impact remyelination potential and the strategies for targeting repair across the multiple sclerosis spectrum.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on headache/migraine presenting to the ER.

Investigators explore a phase 4 trial transitioning CIDP patients from IVIg to efgartigimod, aiming to enhance treatment safety and efficacy.

In this episode, panelists outline the key scientific and clinical challenges in translating remyelination research into effective therapies for patients with MS.

Neurology News Network. for the week ending May 24, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 23, 2025.

Neurologists Ari Green, MD, and Paul Tesar, PhD, discuss the current limitations of remyelination assessment tools in MS and highlight efforts to develop more reliable clinical measures.

A recent study suggests rituximab may benefit CIDP patients, showing improvement in neurofilament levels and clinical outcomes after treatment.

The assistant professor of neurology at Robert Wood Johnson Medical School talked about a collaborative initiative that aims to address AD disparities in Asian and Pacific Islander American populations. [WATCH TIME: 3 minutes]

Researchers reported that both EN001 and insulin improved muscle strength and nerve function in models of Charcot-Marie-Tooth disease type 1A, with combined treatment showing enhanced effects.

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.

New findings confirm vutrisiran's long-term safety and efficacy in treating hereditary transthyretin amyloidosis, enhancing patient quality of life.

In this initial episode, experts Ari Green, MD, and Paul Tesar, PhD, break down the biological foundation and therapeutic importance of remyelination in multiple sclerosis.

Apnimed's AD109 shows promise in treating obstructive sleep apnea, achieving significant results in a landmark Phase 3 trial, paving the way for FDA approval.

The vice president and franchise lead of Autoimmune at Hansa Biopharma discussed the rapid, antibody-cleaving mechanism of imlifidase and its potential to address unmet needs in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

Gene therapy arsa-cel significantly improves nerve function in children with late-infantile metachromatic leukodystrophy, outperforming traditional treatments.